Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ResMed (RMD)

ResMed Q2 fiscal 2026 revenue rises 11% to $1.4 billion; diluted EPS $2.68

Positive Impact 3 of 5 earnings Written later

ResMed reported results for the quarter ended December 31, 2025, with revenue up 11% to $1.4 billion and GAAP diluted earnings per share up 15% to $2.68. The company also declared a quarterly cash dividend of $0.60 per share, with a record date of February 12, 2026, and payment on March 19, 2026.

Key points

  • Revenue of $1,422.8 million, up 11% (9% in constant currency) from $1,282.1 million a year earlier
  • GAAP diluted EPS of $2.68 versus $2.34; non-GAAP diluted EPS of $2.81 versus $2.43
  • Operating cash flow of $340 million; $6 million of restructuring charges recorded in the quarter
  • Quarterly dividend of $0.60 per share; ex-dividend date February 11, 2026

The filing

CompanyResMed (RMD)
Form8-K, current report
Filed with the SECJan 29, 2026, 4:05 PM ET
Accession number0001193125-26-029326

Items reported: 2.02 Results of Operations8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.